After its Phase I success, Invectys raises €4.3 million to enter Phase II with both of its anti-cancer vaccines

 

Paris, July 12th, 2017 – This round brings Invectys’ fundraising to a total of over €23 million from its historical shareholders, who continue to support the company’s development since its inception in 2010. This total includes over €1 million of public funds.

Success of the Phase I clinical trial

This fundraising marks a new success after INVAC-1’s successful Phase I clinical trial, presented in June at the American Society of Clinical Oncology (ASCO)’s world oncology congress. The Phase I trial for the INVAC-1 anti-cancer vaccine involved patients at advanced metastatic stages in solid tumors that were refractory or relapsing to standard treatment. The study took place in 2 AP-HP (Assistance Publique – Hôpitaux de Paris) reference clinical investigation centers, the Saint-Louis hospital and the Georges Pompidou hospital. Survival rate was significantly improved: 60% of patients treated (all at advanced stages of cancer) were still alive between 12 and 28 months after the first administration of INVAC-1, despite their vital prognosis being originally largely unfavorable. Disease stabilization was linked to an immune response induced by the vaccine.

 “This new round of fundraising will allow Invectys to initiate the phase II for INVAC-1, our anti-cancer therapeutic vaccine, through a clinical trial to be started very shortly. The Phase I success opens very promising perspectives in the fight against cancer,” explains Dr. Pierre Langlade Demoyen, Invectys CEO. “This funding demonstrates the support of our investors and the trust they have in our strategy and our technology.”

“This new round of fundraising will allow Invectys to initiate the phase II for INVAC-1, our anti-cancer therapeutic vaccine, through a clinical trial to be started very shortly. The Phase I success opens very promising perspectives in the fight against cancer,” explains Dr. Pierre Langlade Demoyen, Invectys CEO. “This funding demonstrates the support of our investors and the trust they have in our strategy and our technology.”

 

About Invectys

Founded in 2010 at the Pasteur Institute in Paris, Invectys SA is a biopharmaceutical company focused on the development of innovative immuno-oncology treatments. Invectys has raised €38 million. The company has developed a broad pipeline including one platform designed to provide low cost easy-to administer cancer therapies, alone or in combination with other treatments as immune checkpoints antibodies. Invectys products aim to enlist and restoring natural antitumor efficacy from cancer patients.

For more information, please visit www.invectys.com

Press contact :
Invectys – Acorelis – Gilles Petitot – gilles.petitot@acorelis.com – +33 (0)6 20 27 65 94